Advertisement Covers CROI 2017


HIV Clinical Trials Must Enroll More Women

March 6, 2017

People who are designing the studies, who are funding the studies, need to make [enrolling women] a priority.

-- Rena Patel, M.D.

In an interview on behalf of IFARA at CROI 2017, Andy Kaytes spoke with Rena Patel, M.D., and Monica Gandhi, M.D., about HIV in women. Studies have shown that women taking certain forms of hormonal contraceptives have a higher risk of acquiring HIV than those who do not use such pregnancy prevention.

Pregnancy presents a unique opportunity to identify and reach women who may benefit from oral pre-exposure prophylaxis. Studies have not shown adverse birth outcomes for women who took tenofovir disproxil fumarate (TDF, Viread)) during pregnancy.

A newer form of this drug, tenofovir alafenamide (TAF, Vemlidy), may accumulate at lower levels in vaginal tissue than in rectal tissue. Yet, the current clinical trial comparing TDF and TAF has not enrolled any cisgender women. To understand the biological and social differences that contribute to divergent responses to HIV prevention and treatment in women and men, enrolling women in clinical investigations must become a priority.

Watch the video to learn more:

About the panelists:

  • Andy Kaytes, moderator.
  • Rena Patel, M.D., University of Washington, Seattle.
  • Monica Gandhi, M.D., M.P.H., University of California, San Francisco Center for AIDS Research.

The video above has been posted on with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.

Barbara Jungwirth is a freelance writer and translator based in New York.

Follow Barbara on Twitter: @reliabletran.

Related Stories

Women's HIV Status, Viral Suppression Tied to Differences in Cognitive Performance Over Time
What's Your Message to the Trump Administration About the Fight Against HIV?

This article was provided by TheBodyPRO. It is a part of the publication The 24th Conference on Retroviruses and Opportunistic Infections.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.